Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Acorda Therapeutics Inc (NASDAQ:ACOR)

Friday’s trading has closed, but ACOR is being traded in the after-hours session. After-Hours quote »
Delayed Data
As of 1:00pm ET
 +0.13 / +0.34%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Acorda Therapeutics, Inc. engages in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the nervous system. The company's two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. Acorda Therapeutics was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Contact Information

Acorda Therapeutics, Inc.
420 Saw Mill River Road
Ardsley New York 10502
P:(914) 347-4300
Investor Relations:



Mutual fund holders65.02%
Other institutional45.59%
Individual stakeholders17.80%

Top Executives

Ronald CohenPresident, Chief Executive Officer & Director
David LawrenceChief-Business Operations
Michael W. RogersChief Financial Officer
Andrew R. BlightChief Scientific Officer
Anthony O. CaggianoVice President-Research & Development